Stock JAGSNPHARM JAGSONPAL PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jagsonpal Pharmaceuticals Limited

Equities

JAGSNPHARM

INE048B01027

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:47 2024-04-26 am EDT 		5-day change 1st Jan Change
343.6 INR +3.06% Intraday chart for Jagsonpal Pharmaceuticals Limited +7.97% -11.66%
Mar. 08 Jagsonpal Pharmaceuticals Limited Launches Queezy-ER® CI
Feb. 02 Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 704.7 686.4 459.8 2,085 8,214 7,592
Enterprise Value (EV) 1 642.6 338.9 125.7 1,531 7,733 6,506
P/E ratio -6.1 x 9.53 x 5.85 x 12.2 x 41.9 x 28.4 x
Yield 0.37% 0.95% 2.85% 1.26% 1.28% 1.73%
Capitalization / Revenue 0.56 x 0.41 x 0.29 x 1.11 x 3.63 x 3.21 x
EV / Revenue 0.51 x 0.2 x 0.08 x 0.81 x 3.42 x 2.75 x
EV / EBITDA -6.21 x 3.63 x 1.47 x 7.71 x 29.4 x 18.7 x
EV / FCF -43.5 x 1.17 x 1.34 x 9.73 x 61.4 x 15.3 x
FCF Yield -2.3% 85.2% 74.8% 10.3% 1.63% 6.54%
Price to Book 0.72 x 0.66 x 0.41 x 1.71 x 6.28 x 4.78 x
Nbr of stocks (in thousands) 26,198 26,198 26,198 26,198 26,198 26,198
Reference price 2 26.90 26.20 17.55 79.60 313.6 289.8
Announcement Date 8/9/18 9/5/19 9/5/20 9/7/21 8/23/22 8/9/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2018 2019 2020 2021 2022 2023
Net sales 1 1,266 1,668 1,586 1,879 2,261 2,367
EBITDA 1 -103.4 93.35 85.32 198.7 262.8 347.1
EBIT 1 -114 83.19 74.03 187.9 247.6 338.8
Operating Margin -9.01% 4.99% 4.67% 10% 10.95% 14.31%
Earnings before Tax (EBT) 1 -116.3 90.03 94.15 218.7 273.2 348.1
Net income 1 -115.5 72.16 78.71 170.6 195.9 267.2
Net margin -9.13% 4.33% 4.96% 9.08% 8.66% 11.29%
EPS 2 -4.410 2.750 3.000 6.510 7.477 10.20
Free Cash Flow 1 -14.76 288.8 93.95 157.5 125.9 425.6
FCF margin -1.17% 17.31% 5.92% 8.38% 5.57% 17.98%
FCF Conversion (EBITDA) - 309.41% 110.11% 79.23% 47.91% 122.62%
FCF Conversion (Net income) - 400.27% 119.36% 92.3% 64.28% 159.28%
Dividend per Share 2 0.1000 0.2500 0.5000 1.000 4.000 5.000
Announcement Date 8/9/18 9/5/19 9/5/20 9/7/21 8/23/22 8/9/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 62.1 347 334 554 482 1,086
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -14.8 289 93.9 157 126 426
ROE (net income / shareholders' equity) -11.1% 7.13% 7.3% 14.6% 15.5% 18.3%
ROA (Net income/ Total Assets) -5.23% 3.92% 3.27% 7.51% 9.3% 11.8%
Assets 1 2,208 1,843 2,405 2,273 2,106 2,266
Book Value Per Share 2 37.40 39.90 42.40 46.50 49.90 60.60
Cash Flow per Share 2 2.530 2.890 2.010 22.50 9.940 4.220
Capex 1 38.3 22.5 20.7 4.69 4.68 3.18
Capex / Sales 3.02% 1.35% 1.3% 0.25% 0.21% 0.13%
Announcement Date 8/9/18 9/5/19 9/5/20 9/7/21 8/23/22 8/9/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JAGSONPAL PHARMACEUTICALS LIMITED Stock Jagsonpal Pharmaceuticals Limited
-11.66% 109M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JAGSNPHARM Stock
  4. Financials Jagsonpal Pharmaceuticals Limited